BIO 2012 Spotlight: Discussions On Biosimilars, EMs, Partnerships And Global R&D
This article was originally published in PharmAsia News
Executive Summary
During BIO 2012 in Boston last week global pharma leaders discussed many topics related to emerging markets. PharmAsia News takes a closer look.
You may also be interested in...
NIH Royalties For Pfizer, AstraZeneca, Lilly Drugs Remain Open Question In Repurposing Initiative
With collaborative research agreement templates that include many of the details for a licensing agreement, royalties will be the major issue to be resolved if researchers develop new IP for one of the firm’s abandoned compounds.
Pre-Competitive Collaboration Would Help Pharmaceutical Productivity Crisis - If Lawyers Could Get Out Of The Way
CAMBRIDGE, Mass. - Greater R&D collaboration was the theme of the day at the star-studded U.S.-India Chamber of Commerce biopharma and healthcare summit
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.